← Back
Data updated: Mar 10, 2026
Amgen
AMGN OncologyImmunologyMetabolic
Pioneer biotechnology company with strength in oncology and inflammation. Known for biologics innovation including Enbrel, Repatha, and biosimilar portfolio.
$33.4B
Revenue (2024)
$155.0B
Market Cap
-
Trials
48
Approved (2yr)
Key Drugs
Recent Activity
OTEZLA 2025-12-23
Labeling
BKEMV 2025-11-24
Labeling
IMDELLTRA 2025-11-19
Efficacy
BLINCYTO 2025-10-21
Labeling
AMJEVITA 2025-10-16
WEZLANA 2025-09-25
Labeling
WEZLANA 2025-09-25
Labeling
BKEMV 2025-09-17
REMS
AMJEVITA 2025-09-17
Labeling
OTEZLA 2025-08-29
Type 5 - New Formulation or New Manufacturer
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Oncology 44%
9 drugs Phase 3: 25 Phase 2: 15 Phase 1: 70
Immunology 26%
6 drugs Phase 3: 19 Phase 2: 13 Phase 1: 13
Metabolic 15%
0 drugs Phase 3: 15 Phase 2: 4 Phase 1: 20
Gastroenterology 8%
4 drugs Phase 3: 2 Phase 2: 3 Phase 1: 8
Neurology 7%
1 drugs Phase 3: 6 Phase 2: 2 Phase 1: 9
Pipeline Strength Pro
Loading...
Competitors Pro
Takeda big-pharma
Immunology, Oncology, Gastroenterology, Neurology, Metabolic
Eli Lilly big-pharma
Metabolic, Oncology, Immunology, Neurology
EMD SERONO INC biotech
Oncology, Neurology, Immunology, Metabolic, Gastroenterology
Bristol-Myers Squibb big-pharma
Oncology, Immunology, Gastroenterology, Neurology
Pfizer big-pharma
Oncology, Immunology, Gastroenterology
Active (24)
Company Info
- First Approval
- 1989-06-01
- Latest
- 2025-12-23
- Applications
- 27
FDA Sponsor Names
AMGENAMGEN INC